Skip to content

Study · Non-randomized trial · 2023

2 results

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.

Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, Branca D, Bulger PG, Crevecoeur I, Ding FX, Garbaccio RM, Guetschow ED and 29 more

Show all authors

Guo Y, Ha SN, Johnston JM, Josien H, Kauh EA, Koeplinger KA, Kuethe JT, Lai E, Lanning CL, Lee AYH, Li L, Nair AG, O'Neill EA, Stoch SA, Thaisrivongs DA, Tucker TJ, Vachal P, van Dyck K, Vanhoutte FP, Volckaert B, Wolford DG, Xu A, Zhao T, Zhou D, Zhou S, Zhu X, Zokian HJ, Walji AM, Wood HB

Circulation1 May 2023Cited by 119 (Europe PMC)

PMID37125593 (opens in a new tab)PMCIDPMC10325562 (opens in a new tab)DOI10.1161/circulationaha.122.063372 (opens in a new tab)PepBankPUB-37125593
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In healthy adults, single oral MK-0616 doses were associated with over 93% geometric mean reduction in free unbound plasma PCSK9.

    In plain wordsIn healthy adults, free unbound plasma PCSK9 decreased after single oral MK-0616 doses.

    Peptide
    Enlicitide
    Outcome
    DecreaseFree unbound plasma PCSK9
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    PCSK9 reduction
    > 93%
    geometric mean

    Source sentences

    Summary
    In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84-103) of free, unbound plasma PCSK9
    1 context sentence
    Summary · context
    Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics.
  2. 02HumanNon-randomized trialEfficacy outcome

    In participants taking statins, MK-0616 produced a maximum 61% geometric mean LDL cholesterol reduction from baseline after 14 days.

    In plain wordsIn participants taking statins, LDL cholesterol decreased from baseline after MK-0616 treatment.

    Peptide
    Enlicitide
    Outcome
    DecreaseLDL cholesterol reduction
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    20 mg once daily · oral · 14 daysAs given in this study (human).

    Measurements

    Maximum LDL cholesterol reduction
    61%
    geometric mean

    Source sentences

    Summary
    in participants on statin therapy, multiple-oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43-85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616.
    1 context sentence
    Summary · context
    In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.